In the editor: The Ammitor’s Advice Euan Ashley and Rachel Keranen made an interesting case for funding the Nihi as a valuable, proven investment (“Wearing research in Num guarantees a less healthy, not very rich America,” May 28). I live proof that it is true.
At 74, I live every day under the shadow of Alzheimer’s. My mother began to lose his memories of his late 60s, and I was genetically before the same fate. However now I remained sharp thinking, maybe thanks to an experimental week dose of 6 mg of rapamycin.
This medicine is not approved for Alzheimer’s, but in my case, it seems to work. I see that first how promising treatments can provide valuable time of clarity. However I worry every day the benefits will give up, those effects go out or that others cannot qualify for trials. That fear crushed and it shared millions of Americans carrying the same genetic risk.
We wait longer for progress. Decades are required for experiments today to come to the person’s test, and many are unable to approve. The barriers of clinical trials and access access outside access to families scrambling for hope.
I encourage our lawmakers to act today: Increase the Federal investment of Alzheimer research, using experimentation and medicaid medications and Medicaid medicines. We don’t slow down to slow down. Each day of delay is worth valuable memories and valuable life.
Brian Valerie, Dana Point
..
In the editor: The survey cutbacks have annoyed me with my anxiety about the United States cancer patients who finally pay the price. I have heard from patients that clinical trials were closed, affected a 4-year-old childhood leukemia patient that might lose his life.
I was a cancer patient fighting an incurable form of non-hodgkin lymphoma from 2006 until 2018. Diagnosed at the age of 46, I was in continuous treatment until 58. My son was in kindergarten when I was diagnosed and spent his entire K-12 years with a sick mom.
In 2012, when I was in the fifth line of treatment, I heard about a phase of a Phase 1 Clinical Institute of a trait therapy called Car T-Cell Therapy) for my cancer class. The test includes only 17 patients, but the consequences are surprising. Seventy-five percent of patients achieved prolonged absolute forgiveness.
I am determined to stay alive to receive car therapy and 2018, I enrolled in a phase 2 clinical testing of this UCLA therapy. In just one month, I put it on a perfect remission, something that no one of my six previous teries has been fulfilled.
On July 16, I celebrate my seven years of birthday in the car and thanks to my lucky stars for the NIH and the funds of research saved my life. And that little boy is in kindergarten when I was diagnosed is now 25 years old.
Laurie S. Adami, Los Angeles
